Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab Monotherapy and with Durvalumab in Advanced Solid Tumors
NCT03238027Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of axatilimab in solid tumor (7 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 9 months, Maximum Tolerable Dose at 9 months and 1 more. Started Sep 2017; status: completed.
02
Drugs
axatilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03238027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238027.